Maze Therapeutics (MAZE)

Executive Summary

Maze Therapeutics is a clinical-stage biopharmaceutical company leveraging human genetic insights to develop novel therapies for genetically defined diseases. Its two disclosed programs target cardiometabolic and renal conditions: MZE001, an oral NaPi2a inhibitor for hyperphosphatemia in chronic kidney disease, completed Phase 1 in 2022, and MZE828, a long-acting GLP-1 receptor agonist for obesity, is in preclinical development. A third candidate, MZE829, is in Phase 2 for proteinuric kidney disease (NCT06830629) with recruitment ongoing and completion expected by September 2026. The company's Compass Platform and Human Genetics Engine enable systematic target identification from protective genetic variants. Publicly traded since 2023 (NASDAQ: MAZE), Maze has a market cap of ~$1.5B and is advancing its pipeline with a focus on high-unmet-need indications. Upcoming catalysts include key data readouts and program milestones that could drive near-term value.

Upcoming Catalysts (preview)

• Q3 2026MZE829 Phase 2 Top-Line Data35% success
• H2 2026MZE001 Phase 2 Initiation70% success
• Q4 2026MZE828 IND Submission or Phase 1 Start80% success